论文部分内容阅读
目的:探讨MDM2、VEGF在骨肉瘤组织中的表达与骨肉瘤病理分级、转移及预后的关系。方法:采用免疫组织化学(S-P)法检测56例骨肉瘤标本中MDM2、VEGF的表达情况,并分析MDM2、VEGF的表达与病理分级、转移及预后的关联性。同时设8例骨纤维结构不良为阴性对照组。结果:骨肉瘤组织中MDM2表达总阳性率为64.3%(36/56),VEGF表达总阳性率为67.9%(38/56)。骨纤维结构不良组MDM2、VEGF呈阴性表达。骨肉瘤组织中MDM2、VEGF表达与病理分级无关联(P>0.05),而与骨肉瘤的转移和预后相关联(P<0.05)。MDM2和(或)VEGF阳性表达者5年生存率均明显低于阴性表达组(P<0.05);MDM2和VEGF均阳性表达者生存率最低,而二者均阴性表达者生存率最高,MDM2和VEGF均阳性和均阴性表达两组生存率比较,差异具有显著性(P<0.01)。结论:骨肉瘤组织MDM2异常表达者肿瘤的恶性程度增高、预后差,MDM2可能与VEGF共同参与骨肉瘤血管生成并起协同作用。检测骨肉瘤中MDM2和VEGF的表达水平对评价患者的预后有一定价值。
Objective: To investigate the relationship between the expression of MDM2 and VEGF in osteosarcoma and the pathological grade, metastasis and prognosis of osteosarcoma. Methods: The expressions of MDM2 and VEGF in 56 cases of osteosarcoma were detected by immunohistochemistry (S-P). The correlation between the expression of MDM2 and VEGF and the pathological grade, metastasis and prognosis were analyzed. At the same time set 8 cases of poor bone fiber structure as a negative control group. Results: The overall positive rate of MDM2 expression in osteosarcoma was 64.3% (36/56), and the positive rate of VEGF expression was 67.9% (38/56). MDM2 and VEGF were negative in skeletal fiber dysplasia group. The expression of MDM2 and VEGF in osteosarcoma had no correlation with the pathological grade (P> 0.05), but correlated with the metastasis and prognosis of osteosarcoma (P <0.05). The 5-year survival rate of MDM2 and / or VEGF positive expression was significantly lower than that of negative expression (P <0.05). The survival rates of MDM2 and VEGF were the lowest, while the survival rates of both MDM2 and There was significant difference between the two groups in the survival rate of both VEGF positive and negative expression (P <0.01). CONCLUSIONS: In patients with osteosarcoma, the abnormal expression of MDM2 increases the malignancy of the tumor and has a poor prognosis. MDM2 may be involved in the angiogenesis of osteosarcoma with VEGF and may play a synergistic role. Detecting the expression of MDM2 and VEGF in osteosarcoma has some value in evaluating the prognosis of patients.